What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay
Roche is delaying its buyout of Spark Therapeutics for a third time, giving itself one last chance to complete the deal within the first half of 2019.
When the Swiss pharma giant announced in late April it was withdrawing a Premerger Notification and Report Form once again, it expected to refile the documents around May 9. But it now wants to push the refiling day back two weeks, setting May 23 as the new go time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
